HK Stock Market Move | BLOKS(00325) is currently up more than 5%, with the company releasing a series of new product categories. Citigroup is optimistic about the expansion of the target customer base.
Broco (00325) is currently up more than 5%, at the time of writing, up 4.06%, trading at 102.5 Hong Kong dollars, with a turnover of 83.963 million Hong Kong dollars.
BLOKS (00325) is currently up over 5%, as of the time of writing, it is up 4.06% at HK$102.5, with a turnover of HK$83.963 million.
On the news front, according to the official WeChat message from BLOKS, on October 2nd-3rd, the company launched a new category of products called "building blocks cars" at the WF2025 exposition. They also introduced three new product series in the "building blocks people" category: "Nature Collection", "Miracle Q Version", and "Wonder Encounter Edition", as well as more than 40 new building block people products that cater to different needs and cover various price segments. This further demonstrates the vibrant vitality of BLOKS' product ecosystem and signifies that BLOKS is steadily advancing its "all-people, all-price, global" strategy to meet the needs of players worldwide.
Citi released a research report stating that BLOKS is accelerating the launch of new products, prompting them to initiate a 30-day positive observation and set a target price of HK$128 with a "buy" rating. The bank mentioned that at the recent Wonder Festival, BLOKS introduced multiple new product categories and series, indicating that the target audience is expanding. They expect the company to launch more new products at the 2025 China Toy Expo.
Related Articles

EVEREST MED (01952) mRNA tumor vaccine EVM14 continues to break through: after being approved for clinical trials in China, the first patient in the United States successfully enrolled in Phase I.

WALNUT CAP (00905): The net asset value per share at the end of September is approximately HK$0.232.

PROSP INV HOLD (00310): Deng Zidong appointed as executive director
EVEREST MED (01952) mRNA tumor vaccine EVM14 continues to break through: after being approved for clinical trials in China, the first patient in the United States successfully enrolled in Phase I.

WALNUT CAP (00905): The net asset value per share at the end of September is approximately HK$0.232.

PROSP INV HOLD (00310): Deng Zidong appointed as executive director

RECOMMEND

Comprehensive Subsidy Phase-Out: Is China’s Auto Market Nervous Ahead of Golden Week?
30/09/2025

“A+H” Listing Momentum Continues as 20 A‑Share Companies Plan Hong Kong IPOs, PCB Leaders Dongshan Precision and Hoshine Among Them
30/09/2025

Copper Poised as the “New Oil” as Western Grids Lag Behind China, Goldman Sachs Warns
30/09/2025